Why the study?
Chemotherapy is known to cause cardiotoxicity, including severe bradycardia, prompting this report of a patient who developed severe symptomatic bradycardia after receiving idarubicin and cytarabine.
Cytarabine infusion may be associated with transient severe symptomatic bradycardia, highlighting the need for close cardiac monitoring during its administration.
Cytarabine may cause transient bradycardia warranting monitoring; single case leaves association hypothesis-generating.
Cardiotoxicity is damage to the heart muscle, which affects its function. Chemotherapy is known to cause cardiotoxicity along with many other medications and etiologies. Many chemotherapeutic cocktails are known to be associated with cardiotoxicities, such as taxane and cisplatin. Patients might have arrhythmias, severe bradycardia, cardiomyopathy, and even cardiac arrest, so precautions are taken when such medications are started. This report presents a patient who developed severe symptomatic bradycardia after receiving idarubicin and cytarabine and was managed conservatively, along with a literature review of this entity.
No takes yet. Share an insight, caveat, or question.
Albsheer et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: